Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00039741 ↗ Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2/Phase 3 2002-08-01 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗ Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed PENTA Foundation Phase 2/Phase 3 2002-08-01 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗ Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 2002-08-01 Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00084136 ↗ Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 4 2005-05-01 This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 18
HIV-1 Infection 7
HIV 5
HIV Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 26
Acquired Immunodeficiency Syndrome 9
Immunologic Deficiency Syndromes 6
Hepatitis C 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Location Trials
United States 232
Canada 16
Germany 11
South Africa 10
United Kingdom 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Location Trials
California 15
Florida 13
North Carolina 12
New York 12
Illinois 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 8
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Completed 29
Withdrawn 3
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Sponsor Trials
Gilead Sciences 15
National Institute of Allergy and Infectious Diseases (NIAID) 11
AIDS Clinical Trials Group 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Efavirenz, Emtricitabine, And Tenofovir Disoproxil Fumarate
Sponsor Trials
Industry 34
Other 25
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
Merck
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.